Skip to main content
OPCHOption Care Health, Inc.Buy Wait5.0·$22.02+1.66%
Buy WaitModerate Confidence
Investment thesis

Option Care Health offers attractive valuation and consistent earnings execution, but heavy customer and supplier concentration alongside declining earnings estimates and a confirmed downtrend keep the risk profile elevated.

Thesis pillars

  • Attractive Valuation EntryStable
  • Customer Concentration RiskDeteriorating
  • Earnings Estimates DecliningDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Option Care Health, Inc. (OPCH) Stock Analysis

Range Bound setup

Buy WaitVALUE-TRAP 2/5QualityModerate Confidence

Healthcare · Medical Care Facilities

Earnings in 1 day (2026-07-29). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $21.21. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $22.02. Engine's entry $21.21 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors.

Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies plus 109 stand-alone ambulatory infusion suites—delivering anti-infective, immunoglobulin, and biologic therapies under physician direction. Revenue comes from... Read more

$22.02+12.8% A.UpsideScore 5.0/10#28 of 36 Medical Care Facilities
QualityF-score7 / 9FCF yield4.96%
Entry $21.21(50-day MA)Stop $20.06Target $24.43(analyst − 13%)A.R:R 2.2:1
Analyst target$28.08+27.5%12 analysts
$24.43our TP
$22.02price
$28.08mean
$39

Wait for pullback to $21.21. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $22.02. Engine's entry $21.21 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors. Chart setup: RSI 54 mid-range, Bollinger mid-band. Earnings in 1 day. Wait until post-earnings. Score 5.0/10, moderate confidence.

Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 1d<=7d. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-27
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Jul 29, 20261d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Customer: MCOs and non-governmental payers (88.0%)
Concentration risk — Supplier: four vendors
Value-trap signals (2/5): High leverage (D/E 3.4), Material insider selling (18 sells, 0.31% of cap)

Key Metrics

P/E (TTM)16.9
P/E (Fwd)10.6
Mkt Cap$3.4B
EV/EBITDA11.2
Profit Mgn3.6%
ROE15.3%
Rev Growth1.3%
Beta0.65
DividendNone
Rating analysts19

Quality Signals

Piotroski F7/9

Options Flow

P/C1.86bearish
IV78%elevated

Concentration Risks(10-K Item 1A)

  • HIGHCustomerMCOs and non-governmental payers88%
    10-K Item 1A: '88% of our revenue came from MCOs and other non-governmental payers'
  • LOWCustomerlargest payer14%
    10-K Item 1: 'The Company's largest payer represented approximately 14% of its revenue for the year ended December 31, 2025.'
  • LOWregulatoryMedicare and Medicaid12%
    10-K Item 1: 'approximately 12% of the Company's revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid.'
  • HIGHSupplierfour vendors
    10-K Item 1A: 'approximately 68% of our pharmaceutical and medical supply purchases were from four vendors'

Material Events(8-K, last 90d)

  • 2026-05-05Item 5.02LOW
    Chief Growth Officer Christopher L. Grashoff to depart effective May 8, 2026. Entitled to separation benefits under the Amended and Restated Executive Severance Plan conditioned on release of claims. No successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
2.7
Revenue Growth
2.8

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Obv
1.0
Volume
1.1
Macd
3.6
Rsi
4.5
Ma Position
6.0
Volume distribution (falling OBV)Below 200-MA, MA slope -3.5%/30d — confirmed downtrend

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
1.8
Bollinger
4.2
Support Resistance
4.5
GatesMomentum 3.2<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 1d<=7dExecutive change: officer departure/appointmentA.R:R 2.2 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Speculative
RSI
54 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $20.68Resistance $22.46

Price Targets

$20
$21
$24
A.Upside+12.8%
A.R:R2.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Earnings in 1 day - binary event risk
! momentum at 3.2 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-29 (1d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OPCH stock a buy right now?

Wait for pullback to $21.21. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $22.02. Engine's entry $21.21 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors. Chart setup: RSI 54 mid-range, Bollinger mid-band. Earnings in 1 day. Wait until post-earnings. Target $24.43 (+10.9%), stop $20.06 (−9.8%), A.R:R 2.2:1. Score 5.0/10, moderate confidence.

What is the OPCH stock price target?

Take-profit target: $24.43 (+12.8% upside). Target $24.43 (+10.9%), stop $20.06 (−9.8%), A.R:R 2.2:1. Stop-loss: $20.06.

What are the risks of investing in OPCH?

Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors; Value-trap signals (2/5): High leverage (D/E 3.4), Material insider selling (18 sells, 0.31% of cap).

Is OPCH overvalued or undervalued?

Option Care Health, Inc. trades at a P/E of 16.9 (forward 10.6). TrendMatrix value score: 7.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about OPCH?

19 analysts cover OPCH with a consensus score of 4.1/5. Average price target: $28.

What does Option Care Health, Inc. do?Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies...

Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies plus 109 stand-alone ambulatory infusion suites—delivering anti-infective, immunoglobulin, and biologic therapies under physician direction. Revenue comes from reimbursements by MCOs, Medicare, Medicaid, and commercial payers for pharmaceuticals dispensed and nursing services, with 6,528 full-time and 1,738 part-time employees at year-end 2025.

Related stocks: THC (Tenet Healthcare Corporation) · NUTX (Nutex Health Inc.) · UHS (Universal Health Services, Inc.) · SRTA (Strata Critical Medical, Inc.) · ARDT (Ardent Health, Inc.)
Home Stocks OPCH

Latest news

Latest News

GuruFocus89d ago
Yahoo Finance89d agoEarnings
TipRanks89d ago
MarketBeat5d agoEarnings
MarketBeat5d ago
Cổng thông tin điện tử tỉnh Tây Ninh96d ago
Yahoo Finance96d ago
Yahoo Finance97d agoEarnings
StockStory88d ago
Yahoo Finance88d agoEarnings
Finviz88d ago
GuruFocus88d ago
The Malone Telegram88d agoLegal
Quiver Quantitative88d ago
GlobeNewswire88d agoLegal
Seeking Alpha88d ago
Seeking Alpha88d ago
MarketBeat88d agoEarnings
Investing.com88d ago
GuruFocus88d agoEarnings
Loading more...